AstraZeneca and 4 research labs form the A5 Alliance to collaborate on Alzheimer’s disease

Reuters have reported that AstraZeneca and Dr. Steven Paul of Weill Cornell Medical College today announced a first of its kind research collaboration that brings four leading academic research laboratories together with AstraZeneca to work on the disease Alzheimer’s

This new alliance will be called the A5 alliance, the members represent a team of academic scientists with expertise in ApoE biology who will focus on identification, validation, and risk reduction of drug targets for treatment of Alzheimer’s disease.

The A5 Alliance will study a major risk factor for Alzheimer’s disease, the apolipoprotein E4 genotype (ApoE). ApoE is considered second only to age as a risk factor for the development of Alzheimer’s disease. Under the terms of the A5 alliance, AstraZeneca will fund the academic research and members of AstraZeneca’s Neuroscience Innovative Medicines unit will contribute programme management and scientific expertise. The academic alliance members will contribute their disease area knowledge and expertise, as well as lead specific aspects of the research programme in their laboratories.

 

Are you looking for a new role in the pharmaceutical industry?

Click here to see our latest pharmaceutical roles

Posted in: Industry News, News
CK Logo in place of featured image